Status:
COMPLETED
Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Psychosis
Eligibility:
All Genders
17-35 years
Brief Summary
Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the u...
Detailed Description
Schizophrenia is a heterogeneous disorder that likely involves multiple underlying pathological mechanisms, which has plagued attempts to identify rational therapeutic targets. All available antipsych...
Eligibility Criteria
Inclusion
- A diagnosis of first episode psychosis
- Never been treated with an antipsychotic medication
- Between the age of 17 and 35
Exclusion
- Inability to sign informed consent assessed by the Evaluation to sign - - Consent form
- Poorly controlled acute or chronic medical and neurological conditions
- History of head trauma with loss of consciousness for \>2 minutes
- Clinically significant depression, hypomania, or mania
- Active substance abuse or dependence (except for nicotine)
- Suspected substance-induced psychosis
- Treatment with drugs known to affect brain glutamate levels
- Pregnant females
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT03442101
Start Date
April 1 2018
End Date
December 31 2024
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sparks Center
Birmingham, Alabama, United States, 35294